

CLAIMS

What is claimed is:

1. A method for selecting an immunoregulator, said method comprising:
determining a peptide composition's therapeutic effect by administering said composition to a subject prone to showing signs of diabetes; and
determining the development of diabetes in said subject.
2. A method for selecting an immunoregulator, said method comprising:
determining a peptide composition's therapeutic effect by administering said composition to a subject prone to showing signs of septic shock; and
determining the development of septic shock in said subject.
3. The method according to claim 1 wherein said therapeutic effect is further determined by measuring relative ratios and /or cytokine activity of lymphocyte subset-populations in said subject.
4. The method according to claim 2 wherein said therapeutic effect is further determined by measuring relative ratios and /or cytokine activity of lymphocyte subset-populations in said subject.
5. The method according to claim 3 wherein said therapeutic effect is further determined by measuring enzyme levels in said subject.
6. The method according to claim 4 wherein said therapeutic effect is further determined by measuring enzyme levels in said subject.
7. An immunoregulator selected by the method according to claim 1.
8. An immunoregulator selected by the method according to claim 2.

9. A pharmaceutical composition comprising the immunoregulator of claim 7.
10. A pharmaceutical composition comprising the immunoregulator of claim 8.
11. An immunoregulating peptide obtainable or derivable from a urinary metabolite of hCG.
12. A method of preparing a response to an auto-immune disease comprising:
combining two or more immunoregulators said immunoregulators selected from the group consisting of immunoregulator peptides, functional fragments and functional analogues thereof; and
administering said combination to a subject.
13. The method according to claim 12 wherein said immunoregulators comprise immunoregulator peptide and recombinant hCG.
14. The method according to claim 13 wherein said immunoregulator peptide is selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and a functional fragment of any thereof.
15. A method of treating diabetes in a subject comprising:
administering, in a pharmaceutically acceptable manner, pharmaceutically effective amounts of two or more immunoregulators, immunoregulators peptides, functional fragments or functional analogues thereof said subject.
16. The method according to claim 15 wherein said immunoregulators comprise peptide and recombinant hCG.
17. The method according to claim 15 wherein said peptide is selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and a functional fragment thereof.

Sub B1

18. A method of treating sepsis in a subject comprising:
administering, in a pharmaceutically acceptable manner, a pharmaceutically effective amount
of two or more immunoregulators, immunoregulators peptides, functional fragments or functional
analogues thereof to said subject.

Sub
a'

19. The method according to claim 18 wherein said immunoregulators comprise peptide
and recombinant hCG.

20. The method according to claim 18 wherein said peptide is selected from the group
consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and a functional fragment thereof.

Add B2

FOIA b 7 - DATED 12/28/00